📣 VC round data is live. Check it out!

Cerus Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cerus and similar public comparables like Cytek Biosciences, Polynovo, IBA Group, Bioventus and more.

Cerus Overview

About Cerus

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.


Founded

1991

HQ

United States

Employees

281

Website

cerus.com

Financials (LTM)

Revenue: $242M
EBITDA: $14M

EV

$558M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cerus Financials

Cerus reported last 12-month revenue of $242M and EBITDA of $14M.

In the same LTM period, Cerus generated $141M in gross profit, $14M in EBITDA, and had net loss of ($12M).

Revenue (LTM)


Cerus P&L

In the most recent fiscal year, Cerus reported revenue of $234M and EBITDA of $9M.

Cerus is unprofitable as of last fiscal year, with gross margin of 48%, EBITDA margin of 4%, and net margin of (7%).

See analyst estimates for Cerus
LTMLast FY202320242025202620272028
Revenue$242M$234M$156M$180M$206M
Gross Profit$141M$112M$86M$100M$112M
Gross Margin58%48%55%55%54%
EBITDA$14M$9M($26M)($10M)($6M)
EBITDA Margin6%4%(17%)(6%)(3%)
EBIT Margin(2%)(4%)(17%)(8%)(4%)
Net Profit($12M)($16M)($37M)($21M)($16M)
Net Margin(5%)(7%)(24%)(12%)(8%)
Net Debt-$64M---

Financial data powered by Morningstar, Inc.

Cerus Stock Performance

Cerus has current market cap of $541M, and enterprise value of $558M.

Market Cap Evolution


Cerus' stock price is $2.70.

Cerus share price decreased by 11.5% in the last 30 days, and increased by 91.5% in the last year.

Cerus has an EPS (earnings per share) of $-0.08.

See more trading valuation data for Cerus
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$558M$541M-4.8%-11.5%48.4%91.5%$-0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cerus Valuation Multiples

Cerus trades at 2.3x EV/Revenue multiple, and 40.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Cerus

EV / Revenue (LTM)


Cerus Financial Valuation Multiples

As of June 3, 2026, Cerus has market cap of $541M and EV of $558M.

Cerus has a P/E ratio of (46.4x).

LTMLast FY202320242025202620272028
EV/Revenue2.3x2.4x3.6x3.1x2.7x
EV/EBITDA40.6x58.8x(21.2x)(55.7x)(101.2x)
EV/EBIT(107.7x)(64.3x)(21.2x)(39.2x)(64.3x)
EV/Gross Profit4.0x5.0x6.5x5.6x5.0x
P/E(46.4x)(34.6x)(14.4x)(25.9x)(34.6x)
EV/FCF-n/m(11.7x)65.5xn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cerus Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cerus Margins & Growth Rates

Cerus grew revenue by 8% and EBITDA by 106% in the last fiscal year.

In the most recent fiscal year, Cerus reported gross margin of 48%, EBITDA margin of 4%, and net margin of (7%).

See estimated margins and future growth rates for Cerus

Cerus Margins

Last FY202420252026202720282029
Gross Margin48%55%54%57%
EBITDA Margin4%(6%)(3%)8%
EBIT Margin(4%)(8%)(4%)(0%)
Net Margin(7%)(12%)(8%)(2%)
FCF Margin0%5%1%-

Cerus Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth8%15%14%23%
Gross Profit Growth27%15%13%27%
EBITDA Growth106%(62%)(45%)(454%)
EBIT Growth(96%)(46%)(39%)(96%)
Net Profit Growth(60%)(44%)(25%)(60%)
FCF Growth-(118%)(87%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Cerus Operational KPIs

Cerus' revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.4M for the same period.

Cerus' Rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cerus' Rule of X is 64% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cerus
LTMLast FY202320242025202620272028
Rule of 4014%30%---
Bessemer Rule of X26%64%---
Revenue per Employee-$0.8M---
Opex per Employee-$0.4M---
R&D Expenses to Revenue27%29%43%33%33%
Opex to Revenue-52%72%63%59%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cerus Competitors

Cerus competitors include Cytek Biosciences, Polynovo, IBA Group, Bioventus, MiMedx Group, Tactile Medical, Sofwave Medical, NeuroPace, Japan Lifeline and Beta Bionics.

Most Cerus public comparables operate across Medical Devices, Medical Supplies, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Cytek Biosciences1.5x1.5x(463.4x)(186.0x)
Polynovo5.9x5.0x72.0x57.2x
IBA Group0.8x0.8x11.4x10.8x
Bioventus1.4x1.3x6.8x6.7x
MiMedx Group0.9x1.1x3.7x6.4x
Tactile Medical1.4x1.4x10.6x10.1x
Sofwave Medical6.0x-68.7x-
NeuroPace5.7x5.7x(114.3x)(86.6x)

This data is available for Pro users. Sign up to see all Cerus competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cerus

When was Cerus founded?Cerus was founded in 1991.
Where is Cerus headquartered?Cerus is headquartered in United States.
How many employees does Cerus have?As of today, Cerus has over 281 employees.
Who is the CEO of Cerus?Cerus' CEO is William M. Greenman.
Is Cerus publicly listed?Yes, Cerus is a public company listed on Nasdaq.
What is the stock symbol of Cerus?Cerus trades under CERS ticker.
When did Cerus go public?Cerus went public in 1997.
Who are competitors of Cerus?Cerus main competitors include Cytek Biosciences, Polynovo, IBA Group, Bioventus, MiMedx Group, Tactile Medical, Sofwave Medical, NeuroPace, Japan Lifeline, Beta Bionics.
What is the current market cap of Cerus?Cerus' current market cap is $541M.
What is the current revenue of Cerus?Cerus' last 12 months revenue is $242M.
What is the current revenue growth of Cerus?Cerus revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of Cerus?Current revenue multiple of Cerus is 2.3x.
What is the current EBITDA of Cerus?Cerus' last 12 months EBITDA is $14M.
What is Cerus' EBITDA margin?Cerus' last 12 months EBITDA margin is 6%.
What is the current EV/EBITDA multiple of Cerus?Current EBITDA multiple of Cerus is 40.6x.
How many companies Cerus has acquired to date?Cerus hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Cerus has invested to date?Cerus hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cerus

Lists including Cerus

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial